A recently published Phase 2A, randomized, double‐blind, placebo controlled trial assessed the efficacy, safety and tolerability of MEDI0382 (AstraZeneca/Medimmune), a GLP1R/GCGR dual agonist in overweight and obese patients with type 2 diabetes.79 The volunteers given MEDI0382 once a day for 41 days were shown to have a better glucose tolerance in response to a mixed meal test compared to placebo, as well as a reduction in body weight: the mean fall in body weight between baseline and day 41 was 3.84 kg compared to 1.70 kg for placebo. Here, GLP1R is linked to type 2 diabetes mellitus.